Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.

CONCLUSIONS: Our results demonstrate that survivin represents a promising marker for the prediction of cisplatin resistance in BC. In addition the therapy predictive role of HMGA2 should be further investigated. Immunohistochemical analysis of BC samples provides a feasible way for the prediction of cisplatin-resistance and may therefore provide a valuable tool for optimizing treatment decisions in advanced BC. PMID: 31053526 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31053526?dopt=Abstract

Source: Urologic Oncology - April 29, 2019 Category: Urology & Nephrology Authors: Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T Tags: Urol Oncol Source Type: research